Variable Roles of Interleukin-17F in Different Cancers

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Jan 11

PMID 35012470

Authors

Tiina Mikkola

Rabeia Almahmoudi

Tuula Salo

Ahmed Al-Samadi

Affiliations

Soon will be listed here.

Abstract

Background: Interleukin (IL)-17 family is a group of six cytokines that plays a central role in inflammatory processes and participates in cancer progression. Interleukin-17A has been shown to have mainly a protumorigenic role, but the other members of the IL-17 family, including IL-17F, have received less attention.

Methods: We applied systematic review guidelines to study the role of IL-17F, protein and mRNA expression, polymorphisms, and functions, in cancer. We carried out a systematic search in PubMed, Ovid Medline, Scopus, and Cochrane libraries, yielding 79 articles that met the inclusion criteria.

Results: The findings indicated that IL-17F has both anti- and protumorigenic roles, which depend on cancer type and the molecular form and location of IL-17F. As an example, the presence of IL-17F protein in tumor tissue and patient serum has a protective role in oral and pancreatic cancers, whereas it is protumorigenic in prostate and bladder cancers. These effects are proposed to be based on multiple mechanisms, such as inhibition of angiogenesis, vasculogenic mimicry and cancer cell proliferation, migration and invasion, and aggravating the inflammatory process. No solid evidence emerged for the correlation between IL-17F polymorphisms and cancer incidence or patients' prognosis.

Conclusion: IL-17F is a multifaceted cytokine. There is a clear demand for more well-designed studies of IL-17F to elucidate its molecular mechanisms in different types of cancer. The studies presented in this article examined a variety of different designs, study populations and primary/secondary outcomes, which unfortunately reduces the value of direct interstudy comparisons.

Citing Articles

The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review.

Vangilbergen M, Stockman A, Van De Velde A, Garmyn M, Punie K, Hillary T JAAD Int. 2024; 17:71-79.

PMID: 39411241 PMC: 11474213. DOI: 10.1016/j.jdin.2024.06.006.

Kao C, Charmsaz S, Alden S, Brancati M, Li H, Balaji A J Clin Invest. 2024; 134(20).

PMID: 39403935 PMC: 11473156. DOI: 10.1172/JCI176567.

Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.

Song J, Sun X, Wang T, Li C, Yuan L BMC Cancer. 2024; 24(1):1261.

PMID: 39390542 PMC: 11465925. DOI: 10.1186/s12885-024-13016-9.

Interleukin-17F suppressed colon cancer by enhancing caspase 4 mediated pyroptosis of endothelial cells.

Zhou Y, Yang M, Fu R, Liu W, Cai Z, Lin H Sci Rep. 2024; 14(1):18363.

PMID: 39112724 PMC: 11306372. DOI: 10.1038/s41598-024-69436-x.

The Immune Microenvironment Landscape of Pituitary NeuroEndocrine Tumors, a Transcriptomic Approach.

Vela-Patino S, Salazar M, Taniguchi-Ponciano K, Vadillo E, Gomez-Apo E, Escobar-Espana A Genes (Basel). 2024; 15(5).

PMID: 38790160 PMC: 11120841. DOI: 10.3390/genes15050531.

References

Chang S, Mirabolfathinejad S, Katta H, Cumpian A, Gong L, Caetano M . T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A. 2014; 111(15):5664-9. PMC: 3992670. DOI: 10.1073/pnas.1319051111. View

Cecchin E, De Mattia E, Dreussi E, Montico M, Palazzari E, Navarria F . Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Radiother Oncol. 2020; 149:30-37. DOI: 10.1016/j.radonc.2020.04.055. View

Chen Y, Qian T, Zhang D, Yan H, Hao F . Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. Immunotherapy. 2015; 7(9):1023-37. DOI: 10.2217/imt.15.50. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

Krajewski W, Karabon L, Partyka A, Tomkiewicz A, Poletajew S, Tukiendorf A . Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy. Cent Eur J Immunol. 2020; 45(1):37-47. PMC: 7226548. DOI: 10.5114/ceji.2020.94674. View

Park W, Li L, Appana S, Wei W, Stello K, Andersen D . Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and without diabetes. Pancreatology. 2019; 20(1):51-59. PMC: 6983346. DOI: 10.1016/j.pan.2019.11.008. View

He Y, Du Y, Wei S, Shi J, Mei Z, Qian L . IL-17A and IL-17F single nucleotide polymorphisms associated with lung cancer in Chinese population. Clin Respir J. 2015; 11(2):230-242. DOI: 10.1111/crj.12330. View

Qinghai Z, Yanying W, Yunfang C, Xukui Z, Xiaoqiao Z . Effect of interleukin-17A and interleukin-17F gene polymorphisms on the risk of gastric cancer in a Chinese population. Gene. 2013; 537(2):328-32. DOI: 10.1016/j.gene.2013.11.007. View

Wrobel T, Gebura K, Wysoczanska B, Jazwiec B, Dobrzynska O, Mazur G . IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia. J Cancer Res Clin Oncol. 2014; 140(9):1551-5. PMC: 4131129. DOI: 10.1007/s00432-014-1674-7. View

10.

Yang D, Zhou J, Zeng T, Yang Z, Wang X, Hu J . Serum chemokine network correlates with chemotherapy in non-small cell lung cancer. Cancer Lett. 2015; 365(1):57-67. DOI: 10.1016/j.canlet.2015.05.001. View

11.

Almahmoudi R, Salem A, Sievilainen M, Sundquist E, Almangush A, Toppila-Salmi S . Extracellular interleukin-17F has a protective effect in oral tongue squamous cell carcinoma. Head Neck. 2018; 40(10):2155-2165. DOI: 10.1002/hed.25207. View

12.

Xie Y, Sheng W, Xiang J, Ye Z, Yang J . Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest. 2010; 28(6):598-607. DOI: 10.3109/07357900903287030. View

13.

Liu Y, Zhao X, Sun X, Li Y, Wang Z, Jiang J . Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia. Prostate. 2015; 75(16):1844-56. DOI: 10.1002/pros.23058. View

14.

Quan Y, Zhou B, Wang Y, Duan R, Wang K, Gao Q . Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin Dev Immunol. 2012; 2012:258293. PMC: 3463183. DOI: 10.1155/2012/258293. View

15.

Ding L, Hu E, Xu Y, Huang X, Zhang D, Li B . Serum IL-17F combined with VEGF as potential diagnostic biomarkers for oral squamous cell carcinoma. Tumour Biol. 2015; 36(4):2523-9. DOI: 10.1007/s13277-014-2867-z. View

16.

Feng H, Ying R, Chai T, Chen H, Ju H . The association between IL-17 gene variants and risk of colorectal cancer in a Chinese population: A case-control study. Biosci Rep. 2019; 39(11). PMC: 6881208. DOI: 10.1042/BSR20190013. View

17.

Almahmoudi R, Salem A, Hadler-Olsen E, Svineng G, Salo T, Al-Samadi A . The effect of interleukin-17F on vasculogenic mimicry in oral tongue squamous cell carcinoma. Cancer Sci. 2021; 112(6):2223-2232. PMC: 8177764. DOI: 10.1111/cas.14894. View

18.

Zhou B, Zhang P, Wang Y, Shi S, Zhang K, Liao H . Interleukin-17 gene polymorphisms are associated with bladder cancer in a Chinese Han population. Mol Carcinog. 2012; 52(11):871-8. DOI: 10.1002/mc.21928. View

19.

Lee M, Chang J, Liao C, Chen Y, Kuo M, Shen C . Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients. Oncotarget. 2018; 9(11):9825-9837. PMC: 5839404. DOI: 10.18632/oncotarget.23934. View

20.

Li N, Zhang C, Chen Z, Bai L, Nie M, Zhou B . Interleukin 17A and interleukin 17F polymorphisms are associated with oral squamous cell carcinoma susceptibility in a Chinese population. J Oral Maxillofac Surg. 2015; 73(2):267-73. DOI: 10.1016/j.joms.2014.09.009. View